Research Peptides: Guides & Analysis
Research peptides are short chains of amino acids supplied for in vitro and laboratory research only, not for human or veterinary use. This hub collects our compound guides, side-by-side comparisons and research analysis.
Evidence-based research guides, scientific articles, and educational resources on BPC-157, Semaglutide, Retatrutide, metabolic research, tissue repair and more. Updated regularly for laboratory and independent research.
Looking for protocols or compound reference?
This page is news, regulatory coverage and analysis. Reconstitution and blend protocols live in the guide corpus; per-compound mechanism, specifications and storage live in the reference library.
Research Guides
What Is GLP-3? Nickname → Retatrutide (LY3437943)
GLP-3 is informal shorthand for retatrutide, a triple GLP-1/GIP/glucagon receptor agonist — not a hormone or INN. RUO research guide.
Tirzepatide Research-Grade vs Approved Drug Product
Research-grade tirzepatide powder is RUO lab material with lot CoA; approved drug products are separate. Not interchangeable.
All Articles
Copper Peptides Skincare: What Dermatologists Say on GHK-Cu
Copper peptides skincare research centers on GHK-Cu: fibroblast and wound-model data support collagen effects, but human evidence remains small and unblinded.
Retatrutide Phase 3 Trials: TRIUMPH and TRANSCEND Research Guide
Retatrutide Phase 3 trials (TRIUMPH, TRANSCEND-T2D) test LY3437943, a ~4731 Da triple GLP-1/GIP/glucagon agonist, in obesity and type 2 diabetes research.
Brenipatide (LY3537031): Dual GIP/GLP-1 Research Guide
Brenipatide (LY3537031) is Eli Lilly's long-acting dual GIP/GLP-1 receptor agonist being studied in Phase 3 trials for alcohol use disorder and major depressive disorder (NCT07219966, NCT07412756).
MOTS-c FDA Compounding 2026: Mitochondrial Peptide Research Guide
MOTS-c FDA compounding 2026 status affects research access to this 16-amino-acid mitochondrial peptide. Learn what the bulk list means for labs.
Thymosin Alpha-1 Research 2026: Immunity Peptide Study Guide
Thymosin Alpha-1 research covers a 28-amino acid immunomodulatory peptide with documented T-cell activation properties. This guide reviews mechanisms, FDA compounding context, and study parameters for 2026.
PCAC July 2026: Seven Peptides Reviewed for the 503A List
On 23–24 July 2026, FDA’s PCAC agenda listed seven peptides for the 503A bulks list: BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), epitalon, and semax. FDA has not posted summary minutes or vote tallies. Selank, GHK-Cu, and kisspeptin-10 were not on that agenda. The meeting did not add any substance to the 503A or 503B list.
Semaglutide vs Tirzepatide Discontinuation Research: Comparative Rebound Data 2026
Semaglutide vs tirzepatide discontinuation research reveals distinct rebound patterns, persistence rates, and reinitiation behaviors. 2025-2026 studies compare weight regain, metabolic reversal, and implications for high-purity research peptide protocols.
CagriSema vs Retatrutide: ADA 2026 Clinical Comparison Research
CagriSema retatrutide comparison reveals two distinct dual-agonist mechanisms targeting obesity. This guide covers receptor profiles, trial data, and research applications for 2026.
Injectable Peptide Regulation Gap 2026: JAMA Research Analysis
Injectable peptide regulation gaps identified in 2026 JAMA research reveal systemic oversight failures affecting lab-grade compound quality, purity verification, and research integrity.
Epitalon & Semax: Preclinical Neuroprotective Peptide Studies
Epitalon and Semax neuroprotective peptides show distinct bioregulatory mechanisms in preclinical models. This guide reviews published research on telomerase activation, BDNF upregulation, and receptor binding kinetics.
Melanotan-II Peptide Research: Abnormal Mole Development Studies
Melanotan-II peptide research reveals associations between MC1R activation and nevus development. Explore key studies, mechanisms, and safety data for researchers.
GLP-1 Cancer Research 2026: Breast & Prostate Tumor Slowdown Studies
GLP-1 cancer research in 2026 reveals that receptor agonists may slow tumor proliferation in breast and prostate models. This guide reviews the mechanisms, study data, and research implications.
Selank Research Peptide: Anxiolytic Mechanism & Lab Protocols 2026
Selank research peptide is a synthetic anxiolytic analog of Tuftsin that upregulates BDNF and modulates GABAergic transmission. This 2026 guide details molecular targets, intranasal dosing protocols, and lab-grade purity requirements for in-vitro and animal studies.
AI Peptide Antibiotic Optimization: 2026 Research Protocols & Data
AI peptide antibiotic optimization is reshaping 2026 antimicrobial research. Discover machine-learning peptide design, lab-validated assays, and sourcing standards for high-purity research peptides.
FDA Peptide Ban Reversal 2026: What Researchers Must Know Now
FDA peptide ban reversal could reopen 503B bulk list to cosmetic peptides by Q2 2026, restoring GHK-Cu, Argireline, and Matrixyl for dermatology research.
Antimicrobial Peptides in Cancer Research 2026: Mechanisms & Trials
Antimicrobial peptides cancer research shows LL-37 and defensins trigger immunogenic cell death, inhibit angiogenesis, and enhance checkpoint blockade in 2026 pre-clinical models.
FDA Peptide Ban List 2025: What Research Labs Need to Know
FDA peptide ban list 2025 explained: which compounds are restricted, why compounding rules changed, and how research labs can maintain compliant procurement.
Novo Nordisk Triple Agonist Obesity Peptide: GGG Tri-Agonist
Triple agonist obesity peptide research targets GIP, GLP-1, and glucagon receptors simultaneously. This guide covers mechanisms, study data, and sourcing standards for researchers.
A Comprehensive Research Guide: Getting Started with Peptides
Discover the essentials of peptide research, including types, applications, quality assurance, and purity testing methods for reliable and reproducible results.